How should baclofen be initiated, titrated, monitored, and tapered for treatment of spasticity?

Baclofen for Spasticity Management

Direct Answer

Start oral baclofen at 10 mg twice daily, titrate upward by 5–15 mg every 24–72 hours to a target of 30–80 mg/day in divided doses, monitor for sedation and functional improvement at each dose change, and taper gradually (over 1–2 weeks) to avoid withdrawal symptoms if discontinuation is needed. 1

---

Initiation Strategy

Patient Selection

• Oral baclofen is FDA-approved for spasticity from multiple sclerosis and spinal cord injury/disease, but efficacy in stroke has not been established and is therefore not recommended for stroke-related spasticity 2
• Reserve pharmacologic treatment for patients whose spasticity causes pain, impairs skin hygiene, reduces functional ability, or interferes with rehabilitation participation 1
• Attempt non-pharmacologic measures first (antispastic positioning, stretching, splinting, serial casting) before initiating any oral antispasmodic 1

Starting Dose

• Begin at 10 mg twice daily (morning and evening) 1
• The FDA label supports this conservative starting approach to minimize initial sedation 2

---

Titration Protocol

Dose Escalation

• Increase by 5–15 mg per dose every 24–72 hours based on clinical response and tolerability 1
• Target therapeutic range is 30–80 mg/day in divided doses (typically 3–4 times daily) 1
• Maximum FDA-approved dose is 80 mg/day, though some patients may require higher doses under specialist supervision 2

Assessment Timing

• Evaluate the patient within 24 hours of each dose change to assess spasticity reduction and adverse effects 3
• Use standardized measures (Modified Ashworth Scale for tone, spasm frequency scores) to quantify response 4, 5

Response Patterns

• Responders typically show reduction in velocity-dependent resistance and clonus within 1 week at therapeutic doses 6
• If no response occurs at 60–80 mg/day after 1–2 weeks, the patient is likely a non-responder and alternative therapies should be considered 6, 7

---

Monitoring Requirements

Adverse Effects

• Sedation is the most common dose-limiting side effect, affecting 25–75% of patients 7
• Other frequent adverse effects include muscle weakness, nausea, and paresthesia 7
• Avoid concurrent benzodiazepines (e.g., diazepam) as they potentiate CNS depression and may impair neurological recovery 1
• Warn patients about additive CNS effects with alcohol and other depressants 2

Special Populations

• Monitor patients with epilepsy closely, as baclofen may occasionally worsen seizure control and EEG findings 2
• In female patients, palpate for ovarian cysts at follow-up visits (occurs in ~4% on chronic baclofen vs. 1–5% baseline) 2
• Not recommended for children under 12 years due to lack of safety and efficacy data 2

Functional Monitoring

• Reassess whether spasticity reduction translates to functional gains (improved hygiene, dressing, positioning, or gait) 8, 1
• In patients who rely on spasticity for upright posture or ambulation, use baclofen cautiously and monitor for loss of compensatory tone 2

---

Tapering and Discontinuation

Withdrawal Risk

• Never abruptly discontinue baclofen—withdrawal can precipitate hallucinations, seizures, and rebound spasticity 3, 9
• Taper gradually over 1–2 weeks by reducing the daily dose by 10–20% every 2–3 days 3

Weaning Sequence

• If transitioning to intrathecal baclofen, wean oral baclofen first (one drug at a time), beginning after intrathecal therapy is established and effective 3

---

When to Escalate to Intrathecal Baclofen

Indications for ITB

• Severe chronic spasticity refractory to oral agents (failure at maximum tolerated oral dose of ≥80 mg/day) or intolerable side effects at lower doses 8, 1, 5
• Spasticity that causes pain, poor skin hygiene, functional decline, or interferes with positioning/care 1
• Consider ITB as early as 3–6 months after failure of oral therapy in appropriately selected patients 8, 1

ITB Screening and Dosing

• Perform a test bolus of 25–50 mcg intrathecally via lumbar puncture; increase in 10–25 mcg increments until spasms are abolished or optimal function is achieved 4
• Complete spinal cord lesions require higher initial ITB doses (mean 156 mcg/day) compared to incomplete lesions (mean 44 mcg/day) 4
• Start continuous ITB at twice the effective bolus dose (or equal to the bolus dose if response lasted >8 hours) 3
• Use the 500 mcg/mL concentration initially; higher concentrations (1000–2000 mcg/mL) can extend refill intervals but require bridge boluses at refill 3

ITB Dose Titration

• For spinal-origin spasticity, increase daily dose by 10–30% every 24 hours 3
• For cerebral-origin spasticity, increase by 5–15% every 24 hours 3
• Tolerance may develop in patients with complete motor and sensory lesions; doses >1000 mcg/day with poor control warrant immediate catheter evaluation 4, 5

---

Comparative Effectiveness

• Oral baclofen at 30–80 mg/day provides efficacy comparable to botulinum toxin for most muscle groups, except ankle spasticity where botulinum toxin may be superior 1
• Transcutaneous electrical nerve stimulation (TENS) achieves greater reduction on the Modified Ashworth Scale (mean difference −0.42) compared to baclofen, but baclofen remains standard due to FDA approval and established safety 1

---

Key Pitfalls to Avoid

• Do not use baclofen for stroke-related spasticity unless other options are exhausted, as efficacy is not established 2
• Do not combine with benzodiazepines in patients undergoing active rehabilitation 1
• Do not abruptly stop baclofen—always taper to prevent withdrawal 3, 9
• Do not delay ITB referral in patients with dose-limiting sedation or inadequate response at maximum oral doses 8, 1, 7